Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease
Notes for this study:
|Trial Design||Double blind|
|Trial Length||1-7 Days|
|Number of Subjects||50|
|Age Range||45-64, 65+|
|Body Types||Overweight, Average|
Supplementation of 600mg NAC in persons undergoing exacerbations of COPD symptoms failed to improve any measured symptom or lung function more than placebo.